The Food and Drug Administration (FDA) has approved Johnson & Johnson’s therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
J&J’s teclistamab, branded as Tecvayli, is approved for treating adults with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of therapies, the company said.
